Down Syndrome - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Down Syndrome - Pipeline Review, H2 2016

Down Syndrome - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Down Syndrome - Pipeline Review, H2 2016
Published Jul 13, 2016
69 pages — Published Jul 13, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Down Syndrome - Pipeline Review, H2 2016, provides an overview of the Down Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Down Syndrome
- The report reviews pipeline therapeutics for Down Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Down Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Down Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Down Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Down Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in

  
Source:
Document ID
GMDHC8271IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Down Syndrome Overview71
Therapeutics Development82
  Pipeline Products for Down Syndrome Overview81
  Pipeline Products for Down Syndrome Comparative Analysis91
Down Syndrome Therapeutics under Development by Companies101
Down Syndrome Therapeutics under Investigation by Universities/Institutes111
Down Syndrome Pipeline Products Glance123
  Clinical Stage Products121
  Early Stage Products131
  Unknown Stage Products141
Down Syndrome Products under Development by Companies151
Down Syndrome Products under Investigation by Universities/Institutes161
Down Syndrome Companies Involved in Therapeutics Development177
  AC Immune SA171
  Aelis Farma SAS181
  Cortice Biosciences, Inc.191
  Eisai Co., Ltd.201
  F. Hoffmann-La Roche Ltd.211
  NeuroNascent, Inc.221
  Transition Therapeutics Inc.231
Down Syndrome Therapeutics Assessment249
  Assessment by Monotherapy Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration292
  Assessment by Molecule Type312
Drug Profiles3330
  ACI-24 Drug Profile332
  ALZ-801 Drug Profile353
  APH-1104 Drug Profile381
  basmisanil Drug Profile391
  D-217 Drug Profile401
  donepezil hydrochloride Drug Profile412
  Dosmir Drug Profile431
  ELND-005 Drug Profile446
  minocycline Drug Profile501
  NNI-351 Drug Profile511
  NNI-362 Drug Profile522
  Pentylenetetrazol Drug Profile542
  Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome Drug Profile561
  Small Molecule to inhibit DYRK1A for CNS Diseases Drug Profile571
  Small Molecules for Down Syndrome Drug Profile581
  Small Molecules to Inhibit OLIG2 for Down Syndrome Drug Profile591
  Stem Cell Therapy to Activate ZSCAN4 for Down Syndrome and Edwards Syndrome Drug Profile601
  xamoterol fumarate Drug Profile612
Down Syndrome Discontinued Products631
Down Syndrome Product Development Milestones644
  Featured News &Press Releases641
    Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome641
    Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics651
    Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome651
    Apr 07, 2014: Transition Therapeutics Announces Development Update652
    Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome671
    Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome671
    Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome671
Appendix682
  Methodology681
  Coverage681
  Secondary Research681
  Primary Research681
  Expert Panel Validation681
  Contact Us681
  Disclaimer691

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Down Syndrome - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Down-Syndrome-Pipeline-Review-H2-2016-2088-16172>
  
APA:
Global Markets Direct - Market Research. (2016). Down Syndrome - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Down-Syndrome-Pipeline-Review-H2-2016-2088-16172>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.